Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2020 16:05 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will...
August 17, 2020 07:00 ET | Source: Abeona Therapeutics Inc.; Taysha Gene Therapies

Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease

NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a...
August 11, 2020 16:46 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics gibt Geschäftsergebnisse für das zweite Quartal und Unternehmensneuigkeiten bekannt

Weitere Patienten in den klinischen Programmen zu RDEB, MPS IIIA und MPS IIIB behandelt Allgemeine Abstimmung mit dem CHMP über Pläne zur EU-Registrierung von ABO-102 für MPS IIIA Daten aus RDEB-...
August 11, 2020 16:46 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics annonce ses résultats financiers et mises à jour du deuxième trimestre

Des patients supplémentaires ont reçu des doses dans le cadre des programmes cliniques sur l'EBDR, le MPS IIIA et le MPS IIIB Alignement général par rapport aux plans d'enregistrement dans l'UE de...
August 10, 2020 16:01 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates

Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
July 10, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting

EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial...
July 09, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer

NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
July 08, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies

NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
June 18, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Announces Upcoming Data Presentations at the Society for Pediatric Dermatology 45th Annual Meeting

NEW YORK and CLEVELAND, June 18, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to...
June 17, 2020 07:30 ET | Source: Abeona Therapeutics Inc.

Abeona Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors

NEW YORK and CLEVELAND, June 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced Board of Director appointments...